-
Chang-Wook Jung,
Jeong-Rang Jo,
Sang-Han Lee,
Yu-Kyoung Park,
Nak-Kyun Jung,
Dae-Kyu Song,
JaeHoon Bae,
Ki-Young Nam,
Jung-Sook Ha, In-Sook Park,
Gy-Young Park,
Byeong-Churl Jang,
Jong-Wook Park
[show abstract]
[hide abstract]
ABSTRACT: Evidence suggests anti-tumor activities of glucosamine-hydrochloride (GS-HCl). In the present study, we investigated anti-proliferative, growth suppressive and/or pro-apoptotic effects of GS-HCl on YD-8 human oral squamous cell carcinoma (OSCC) cells. Fundamentally, treatment with GS-HCl strongly inhibited proliferation and induced apoptosis in YD-8 cells, as determined by MTS and DNA fragmentation analyses. Of further note, as measured by Western analyses, GS-HCl treatment led to activation of caspase-3, cytosolic accumulation of cytochrome c, down-regulation of Mcl-1 and HIF-1α, up-regulation of GRP78, an indicator of ER stress, and generation of ROS in YD-8 cells. Importantly, results of pharmacological inhibition studies showed that treatment with z-VAD-fmk, a pan-caspase inhibitor, but not with vitamin E, an anti-oxidant strongly blocked the GS-HCl-induced apoptosis in YD-8 cells. Analyses of additional cell culture works further revealed that GS-HCl had a strong growth suppressive effect on not only YD-8 but also YD-10B and YD-38, two other human OSCC cell lines. These findings collectively demonstrate that GS-HCl has anti-proliferative, anti-survival, and pro-apoptotic effects on YD-8 cells and the effects appear to be mediated via mechanisms associated with the mitochondrial-dependent activation of caspases, down-regulation of Mcl-1, and induction of ER stress. Considering HIF-1α as a tumor angiogenic transcription factor, the ability of GS-HCl to down-regulate HIF-1α in YD-8 cells may further support its anti-cancer property. It is thus suggested that GS-HCl may be used as a potential anti-cancer drug against human OSCC.
Toxicology in Vitro 02/2012; 26(1):42-50. · 2.78 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Pulmonary arterial stenosis is a relatively common complication after corrective operation of congenital heart disease. Unilateral stenosis of pulmonary arteries could result in decrease perfusion of affected lung, pulmonary regurgitation, or elevation of right ventricular pressure. Eventually there are increasing risks of right ventricular failure, arrhythmia, or sudden death. However we have limited data of pulmonary arterial stent in paediatric population as the treatment of branch pulmonary stenosis. This study aimed at validating the effectiveness and investigating complications of pulmonary arterial stent implantation in a single institution during mid-term follow up period.
A total of 42 patients (50 stents) were implanted for treating branch pulmonary arterial stenosis. We used cardiac catheterization for comparing diameter after stent implantation directly and lung perfusion scan indirectly. We also investigated any adverse effect relating the procedure.
Percent stenosis of stenotic lesions were decreased from 54.1±10.7% to 22.8±12.5% (p<0.001) and degree of decrement in affected lung perfusion was declined from 22.7±8.0% to 10.3±9.0% (p<0.001) immediately and lasts during mid-term follow up period. Complication rate relating the procedure was 12% (6 out of 12) and there was no mortality case.
This series showed immediate and short term effectiveness of pulmonary arterial stent in congenital heart defects. We concluded that percutaneous transcatheter implantation of pulmonary arterial stent was safe and effective during short and mid-term follow up period.
Korean Circulation Journal 01/2012; 42(1):40-5.
-
[show abstract]
[hide abstract]
ABSTRACT: Surgical skill and strategy for the correction of tetralogy of Fallot (TOF) have improved and resulted in satisfactory outcomes. However, prematurity and low birth weight continue to remain risk factors for poor outcomes. We present a case of a 2,150 g neonate born with TOF, in whom palliation was achieved with right ventricular outflow tract (RVOT) stenting. Seventy-seven days after the procedure, stenosis of RVOT below the stent was identified. At that time his body weight was 4.9 kg and total corrective surgery was deemed feasible. Eight months following surgical repair, the patient remained well without medical intervention. RVOT stenting may be a viable interim procedure while waiting for a low birth weight neonate born with TOF and prostaglandin E1 dependency to reach optimal weight to undergo corrective surgery.
Korean Circulation Journal 12/2011; 41(12):744-6.
-
In-Sook Park,
Jeong-Rang Jo,
Hua Hong,
Ki-Young Nam,
Jong-Bae Kim,
Sang-Hee Hwang,
Mi-Sun Choi,
Nam-Hee Ryu,
Hyun-Jung Jang,
Sang-Han Lee,
Chin-Soo Kim,
Tae-Geon Kwon,
Gy-Young Park,
Jong-Wook Park,
Byeong-Churl Jang
[show abstract]
[hide abstract]
ABSTRACT: NSAIDs and COX-2 inhibitors show anti-cancer activities in many cancer cells. In this study, we investigated the effects of NSAIDs (aspirin or indomethacin) and COX-2 inhibitor (NS-398) on growth of YD-8 human oral squamous carcinoma cells. Interestingly, among drugs tested, aspirin showed strongest inhibitory effects on viability and survival of YD-8 cells. Profoundly, aspirin treatment resulted in severe cell shrinkage and nuclear DNA fragmentation in YD-8 cells, suggesting the aspirin-induced apoptosis in YD-8 cells. Data of Western blot further demonstrated that aspirin treatment caused activation of caspases, down-regulation of Mcl-1 protein, dephosphorylation of ERK-1/2 and AKT, and also IkappaB-alpha proteolysis-dependent NF-kappaB activation in YD-8 cells. Aspirin, however, had no effect on expressions of Bcl-2, XIAP, and HIAP-1 in YD-8 cells. Importantly, pretreatment with z-VAD-fmk, a pan-caspase inhibitor blocked the aspirin-induced apoptosis and Mcl-1 down-regulation in YD-8 cells. These findings collectively suggest that aspirin induces apoptosis in YD-8 cells and the induction may be correlated to activation of caspases, caspase-dependent Mcl-1 proteolysis, inactivation of ERK-1/2 and AKT, and activation of NF-kappaB. It is suggested that aspirin may be applied a potential anti-cancer drug against human oral squamous carcinoma.
Toxicology in Vitro 04/2010; 24(3):713-20. · 2.78 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: The purpose of the study was to evaluate whether the induction of unilateral masticatory muscle dysfunction can alter the skeletal growth patterns.
Twenty-one white male New Zealand rabbits (4 weeks old) were divided into 3 groups of 7 subjects: group 1 served as the control to study normal craniofacial growth. In groups 2 and 3, rabbits were injected with 5 units and 15 units of Botulinum toxin A (BTXA) into the right masseter muscle, respectively. The effect of a neuromuscular blockade of masseteric activity on craniofacial growth was evaluated with 3 samples of serial computed tomography (CT) scans with a slice thickness of 0.625 mm, taken at 4 weeks (base line), 8 weeks (endpoint of prepubertal craniofacial growth), and 24 weeks (after pubertal growth).
The ipsilateral mandibular ramus height, zygomatic arch length, and masseteric length did not develop as much as those of the contralateral side after pubertal growth. At age 24 weeks, the masseter muscle volume asymmetry index reached -13.8% (group 2), -18.4% (group 3), and -1.6% for the control group. The ipsilateral side of the hemimandible showed less bone volume after 8 weeks but it showed partially recovered symmetry at 24 weeks. The maxillomandibular incisor midline and transverse molar discrepancies were not evident in any of the groups.
The BTXA injection can be an effective method in inducing site-specific muscular hypofunctions so that masticatory muscle-craniofacial bone interaction can be investigated efficiently. The result showed that the unilateral atrophy of the masseter muscle in the growing subjects influenced the morphology of the local skeletal sites. This did not, however, result ultimately in mandibular midline asymmetry or right-left asymmetry in hemimandibular volume after growth. The results imply that alterations in specific masticatory muscle function can be compensated by the growth of other structural components.
Journal of Oral and Maxillofacial Surgery 09/2007; 65(8):1530-7. · 1.64 Impact Factor
